Tulassay Z, Flautner L, Vadász A, Fehérvári I
Department of Medicine, Semmelweis University, Medical School, Budapest, Hungary.
Aliment Pharmacol Ther. 1993 Jun;7(3):323-5. doi: 10.1111/j.1365-2036.1993.tb00104.x.
The efficacy of the long-lasting somatostatin analogue, octreotide, in the treatment of high-output pancreatic fistulas was investigated in this prospective, open study. Sixteen patients with post-operative pancreatic fistulas were treated with subcutaneous injections of octreotide 0.1 mg b.d. The output of the fistulas before the somatostatin therapy ranged between 190 and 570 ml/day. The therapy was begun on average 17 days following the appearance of the fistula (range 4 to 35 days). The decrease in volume one day after initiation of therapy ranged from 26% to 69%. By the third day of treatment the fistula volume decreased to 0-45% of the initial output. The treatment resulted in the closure of 14 of the 16 fistulas; the time to closure ranging from 3 to 15 days. The results suggest that octreotide is a useful adjuvant agent in the treatment of an external pancreatic fistula.
在这项前瞻性开放性研究中，对长效生长抑素类似物奥曲肽治疗高流量胰瘘的疗效进行了调查。16例术后胰瘘患者接受皮下注射奥曲肽，剂量为0.1mg，每日两次。生长抑素治疗前瘘管的引流量在190至570毫升/天之间。治疗平均在瘘管出现后17天开始（范围为4至35天）。治疗开始后一天，引流量减少幅度为26%至69%。到治疗第三天，瘘管引流量降至初始引流量的0 - 45%。治疗使16例瘘管中的14例闭合；闭合时间为3至15天。结果表明，奥曲肽是治疗外源性胰瘘的一种有用辅助药物。
